Cellular Physiology and Biochemistry is a premier Open Access journal published by the prestigious Cell Physiol Biochem Press GmbH & Co, dedicated to advancing research in the fields of physiology, biochemistry, and molecular biology. Since its inception in 1987 and transitioning to an Open Access model in 2013, the journal has established itself as a vital resource for the dissemination of high-quality research and reviews, showcasing innovative methodologies and groundbreaking findings in cellular processes. With an impressive ranking in the 2023 Scopus category as Q2 in Physiology and a robust percentile of 61, Cellular Physiology and Biochemistry is committed to fostering academic dialogue among researchers, professionals, and students alike. This journal not only provides unrestricted access to its articles, but also promotes the global sharing of knowledge, which is essential for the advancement of our understanding in these vital scientific areas. The journal's editorial team is dedicated to ensuring the highest standards of academic rigor and relevance, making it an indispensable addition to the libraries of those engaged in the life sciences.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

CELL BIOLOGY INTERNATIONAL is a prestigious academic journal dedicated to the rapidly evolving field of cell biology, publishing high-quality research aimed at understanding cellular processes and their implications in various biological contexts. Published by Wiley, this journal has established its relevance with an H-Index that reflects its robust citation impact and a commendable Scopus Rank of #111 out of 285 in the field of Biochemistry, Genetics, and Molecular Biology, positioning it in the 61st percentile. Although it operates under a traditional subscription model, its influential insights are crucial for researchers, professionals, and students alike who are seeking cutting-edge developments in cellular mechanisms and their applications in medicine. The journal spans contributions dating back to 1993, providing a rich archive of knowledge that continues to shape the discourse within the scientific community. With a strong category ranking of Q3 in Cell Biology and Q2 in Medicine (miscellaneous) as of 2023, CELL BIOLOGY INTERNATIONAL stands as a reliable platform for disseminating transformative science in the cellular domain.

FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

FOLIA BIOLOGICA, published by Charles University Prague, First Faculty of Medicine, is an esteemed academic journal that has been contributing to the fields of Biochemistry, Cell Biology, Developmental Biology, Genetics, Immunology, and Molecular Biology since its inception in 1961. With an ISSN of 0015-5500, this journal serves as a vital platform for researchers and professionals to disseminate their findings and advance knowledge within these disciplines. Despite its current Category Quartiles ranking in the lower tiers (Q3 and Q4), FOLIA BIOLOGICA continues to provide valued insights and foster scholarly dialogue, particularly in its paralleled fields. The journal is headquartered in Prague, Czech Republic, and operates without Open Access options, which emphasizes its focus on curated, peer-reviewed content essential for academicians and students. By bridging theoretical and practical knowledge, FOLIA BIOLOGICA remains committed to enriching the scientific community and serving as a cornerstone for future research innovations.